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Background and aims: Current antiviral therapy for HCV genotype (GT) 3‐associated cirrhosis achieves 
suboptimal sustained virological response (SVR) rates. Daclatasvir (DCV) + Sofosbuvir (SOF) ± 
ribavirin (RBV) is the only all‐oral recommended option due to lower SVR rates of SOF/LDV in patients 
with cirrhosis. We aimed to evaluate the efficacy and safety of 12 and 24‐week SOF+DCV or SOF/LDV 
± RBV in a real‐life cohort of GT3 patients with cirrhosis.  
 
Patients and methods: Multicenter observational study from two different databases: HepaC‐AEEH and 
Community of Madrid Regional registry. All HCV‐cirrhotic patients mono‐infected by GT3 and treated 
with SOF plus a NS5A inhibitor (DCV or LDV) ± RBV between May 2014 and October 2015 were 
included.  
 
Results: 282 patients were included: 83% male, age 54 years (26‐82), 124 (44%) treatment‐experienced, 
48 (17%) decompensated, 130 (46%) FibroScan >20 kPa and 65 (23%) MELD score>10.195 (69%) 
received SOF+DCV and 87 (31%) SOF/LDV. Over‐all, 88% received RBV. The addition of RBV and 
extension to 24 weeks were higher in the SOF/LDV group (95% vs. 84%, p=0.004; 83% vs. 62%, 
p<0.001). A higher percentage of decompensated patients were treated with DCV (21% vs. 10%, 
p=0.029). 208 patients have reached week 12 of follow‐up. Overall SVR12 was 93.8% (195/208), 94% 
with SOF+DCV and 93.5% with SOF/LDV. SVR12 rates are summarized in table. 13 failures were 
observed (9 relapses, 1 virological failure, 3 deaths). Previous treatment did not impact on SVR. Platelet 
<75,000/mL was the only factor associated with nonSVR12 (RR: 3.50; 95%CI 1,23‐9,94; p=0.019). In 
patients with MELD <10 or albumin >3.5 mg/dL, type of NS5A inhibitor did not impact on SVR12 (93% 
vs 97%, RR 0.96, 95%CI 0.89‐1.04; 93% vs 96%, RR 0.97, 95%CI 0.90‐1.05, respectively). Only 16 
patients (5.7%) presented serious adverse events (SAE), including 3 deaths (1.1%) and 6 discontinuations 
(3.2%). Percentage of SAEs and deaths was higher in decompensated patients (18% vs. 3.1%, p<0.001, 
4% vs. 0.4%, p=0.08). SVR12 of all cohort will be presented at the meeting.  
 
Conclusions: SOF/LDV+RBV achieved high SVR12 rates in GT3 patients with compensated cirrhosis, 
similar to SOF+DCV, both with low rates of serious adverse events.  
  SVR n (%) 95 CI 
SOF+DCV+RBV Child A 82/87 (94,2%) 0,87-0,98 
SOF+DCV+RBV Child B/C 17/18 (94,4%) 0,72-0,99 
SOF+DCV Child A 10/11 (91,0%) 0,58-0,99 
SOF+DCV Child B/C 14/15 (93,3%) 0,68-0,99 
SOF/LDV+RBV Child A 61/64 (95,3%) 0,86-0,99 
SOF/LDV+RBV Child B/C 7/9 (77,7%) 0,39-0,97 
SOF/LDV Child A 4/4 (100%) 0,39-1 
SOF/LDV Child B/C 0/0 NA 
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